Navigation Links
Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Date:1/7/2008

Ortho-McNeil to Continue Investigation of GDIR Agonists Under its

Partnership with Arena

SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that initial clinical study results for APD668, an oral drug candidate discovered by Arena and being investigated for the treatment of type 2 diabetes under a partnership with Ortho-McNeil Pharmaceutical, Inc., suggest that Glucose-Dependent Insulinotropic Receptors, or GDIRs, may improve glucose control in patients with type 2 diabetes.

Ortho-McNeil's initial clinical studies evaluated healthy volunteers and patients with type 2 diabetes in randomized, double-blind, placebo-controlled trials evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple (14 day) escalating doses of APD668. Based on the data from those studies, Ortho-McNeil has decided to put APD668 on hold and has advanced a potentially more potent Arena discovered GDIR agonist into preclinical development.

"We are encouraged by the clinical study results supporting GDIR agonists as effective modulators of glucose homeostasis in patients with type 2 diabetes, and we look forward to the results of Ortho-McNeil advancing another of Arena's GDIR compounds into development," stated Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer.

About the Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor, or GPCR, discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. Stimulation of the GDIR is intended to more efficiently
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
2. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
3. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CORALVILLE, Iowa , Sept. 23, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... received a No Objection Letter (NOL) from Health ... Canada for its lead product candidate ... hydrocodone prodrug in development for acute moderate to ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... 23, 2014  Medela announced today that it has ... assigning Medela as the exclusive distributor of the ABC ... Medela Enteral Feeding Pump. Through this agreement, Medela will ... and healthcare professionals by offering a comprehensive set of ... Pump is integral to the delivery of human milk ...
Breaking Medicine Technology:KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2
... 14, 2011 Novocure, a commercial stage private ... former senior OSI Pharmaceuticals executives to its Global ... for bringing the company,s new tumor treating fields ... Peter M. Melnyk has joined Novocure as ...
...  SRI International has been awarded a contract worth up ... Institute of Allergy and Infectious Diseases (NIAID), part of ... will allow SRI to continue a program that supports ... the translation of basic research into clinical applications. Since ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 2SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 3
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 23, 2014 What information do ... National Quality Forum (NQF) released a report ( ... and an infographic ( http://bit.ly/1tX3lzA ) resulting from ... healthcare, how patients define affordability, and what information ... the best possible healthcare at the lowest possible ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... obese as teenagers could grow up to earn up ... weight. So says Petter Lundborg of Lund University, Paul ... University and Lund University, all in Sweden. The team ... the United States, and the results are published in ... analyzed large-scale data of 145,193 Swedish-born brothers who enlisted ...
Breaking Medicine News(10 mins):Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2
... A path breaking research published today seems to have ... be able to manufacture their own sperms. Lesbian couples// ... ,Researchers have applied for permission to generate synthetic ... this move will be ethical is a question that ...
... the key to not only stopping heart attacks in ... Researchers at Mount Sinai School of Medicine have shown ... novel contrast agent know as N1177 can detect dangerous, ... findings may help physicians diagnosis a heart attack before ...
... Alirajpur in Jhabua district, beat his wife to death. Reason? ... another young man killed his brother with an arrow when ... owned by him. ,Often the reasons for murders ... entering the neighbour's territory or someone's refusal to lend a ...
... - If you are obese, blame it on your gene. A ... called FTO portray mutation in both their copies, then such people ... people who possess normal copies of the gene. ,Researchers ... of what is happening, this research could give us an answer ...
... M.D., director of the Yale Child Study Center and ... discuss the expansion of the Center’s specialty clinical services ... at Greenwich Library, 101 W. Putnam Ave., Greenwich. ... new clinical services, which will also benefit clients from ...
... Northeastern states in the US are stepping up their efforts ... mercury emissions.// ,Throughout the Northeast, mercury contamination ... that occurs naturally. , It is released ... generating plants. ,Smokestack emissions drift across state ...
Cached Medicine News:Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 3Health News:Efforts Underway to Fight Alcoholism Among Tribals 4Health News:US States Get Ready to Fight Mercury Pollution 2